I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
1.070
-0.020 (-1.83%)
Jan 22, 2025, 4:00 PM EST - Market closed
I-Mab Employees
I-Mab had 220 employees as of December 31, 2023. The number of employees decreased by 158 or -41.80% compared to the previous year.
Employees
220
Change
-158
Growth
-41.80%
Revenue / Employee
$15,064
Profits / Employee
-$374,051
Market Cap
87.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | 185 | 51 | 38.06% |
| Dec 31, 2018 | 134 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
IMAB News
- 15 days ago - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PRNewsWire
- 17 days ago - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - PRNewsWire
- 2 months ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 2 months ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire
- 2 months ago - I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer - PRNewsWire
- 3 months ago - I-Mab to Release Q3 2024 Financial Results on November 14, 2024 - PRNewsWire
- 3 months ago - I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 - PRNewsWire
- 3 months ago - I-Mab to Participate at the Truist Securities BioPharma Symposium - PRNewsWire